The content of this website is intended for United States audiences only.

Report an Adverse Event
/-/media/project/gileadclinicaltrial/header/arrow-right-img.svg

Our Commitment to
Clinical Research for
Breast Cancer

For over 30 years, Gilead has developed medicines for life-threatening diseases like breast cancer. Your participation in a clinical trial is a personal, yet crucial, decision. We hope that you find the information on this page educational and informative. Thank you for considering a Gilead trial!

Ribbon

Featured Trials

bg-featured-card-ribbon

Triple Negative Breast Cancer

ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab
ascent 07

ASCENT-07

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan in Patients with HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy.

What are we studying?

Learn more about our areas of research and see if one of our clinical trials might be right for you.

HR+/HER2- Breast Cancer

  • Breast cancer cells have receptors that can be activated by hormones such as estrogen and progesterone hormones and or proteins such as the human epidermal growth factor
  • Cancer growth is fueled by hormones or proteins
  • Treatment is determined by receptor type and can include chemotherapy, hormone therapy surgery or radiation
  • ~69% of all breast cancers are hormone receptor positive/human epidermal growth factor receptor 2 negative
bg-hrher2-breast-cancer

Triple Negative Breast Cancer (TNBC)

  • Triple negative breast cancer diagnosis occurs when cancer cells test negative for estrogen, progesterone and human epidermal growth factor receptor
  • ~15% of all breast cancer is triple negative breast cancer
  • TNBC is an aggressive form of breast cancer and disproportionately affects Black women


bg-hrher2-breast-cancer
bg-tnbc-breast-cancer
Breast Cancer Feature Banner

What is Metastatic Breast Cancer?

Talking to your Family About Metastatic Breast Cancer Diagnosis.

What Happens When You Join a Breast Cancer Clinical Trial?

Patient Steering Council Advisors for TNBC

We thank these courageous women for sharing their passion and expertise.

ricki2x
Ricki F.

Founder/ CEO The Black Breast Cancer Alliance

  • As a Stage 3A Triple Negative Breast Cancer Survivor/Thriver, Ricki's personal purpose, passion. mission, ministry and blessing is to bring focus, attention, research and action to eradicating Black Breast Cancer, and supporting and coaching what she calls her "Breasties" through their breast cancer experience.
  • Ricki is an award-winning seasoned marketing veteran that has transformed her strategic acumen into breast cancer advocacy. Ricki co-founded and serves as CEO of TOUCH, The Black Breast Cancer Alliance.
  • Ricki founded and serves as co hostfor "TheDoctorlsin," a weekly live web series on the BlackDoctor.org Facebook page that reaches over 2 million viewers.
  • She writes regularly for the Black press including BlackDoctor.org, Black Health Matters and The Cincinnati Herald.
maimah2x
Maimah K.

Founder/ CEO Tigerlilly Foundation

  • Maimah is a TNBC Survivor. On February 2. 2006, at the age of 32, Maimah was diagnosed with Stage 2 breast cancer, with no family history of it.
  • Maimah founded Tigerlily Foundation in 2006, while undergoing chemotherapy. Its mission is to help young women with breast cancer as they face the disease and embark on the grueling path to recovery. Maimah grew Tigerlily Foundation from a concepto a national organization, with hundreds of volunteers nationwide, providing breast health, wellness and transformational programs to young women across the country.
  • In 2010, Maimah published her memoir, Fearless: Awakening to my Life's Purpose Through Breast Cancer, which was a best-seller. In 2013, she founded Bliss Magazine, a quarterly publication that inspires others to live their soul purpose.
shont2x
Shonta C.

EVP Patient Advocate Foundation

  • Shonta leads the development and execution of strategic initiatives to expand Patient Advocacy Foundation's approach to achieve health equity through community and national level partnership engagement and mobilization.
  • She brings to this role nearly 20 years of non-profit and public sector middle and senior level experience that spans public health, women's health and behavioral health. She uses her voice to elevate the health and quality of life of people with cancer and other chronic diseases.
  • Shonta works with community stakeholders to reduce obstacles to optimal health for people living with disease in low-income neighborhoods. She co-chaired the National Comprehensive Cancer Network's Elevating Cancer Equity Working Group, formed to advance equity in oncology.
hayleydinerman2x
Hayley D.

Executive Directive TNBC Foundation

  • Hayley is a co-founder of the Triple Negative Breast Cancer Foundation and has served on the Board of Trustees since its inception. The foundation was built on friendship. In 2005 Hayley and other young mothers, who had recently formed a playgroup for their young children, learned that their friend had triple-negative breast cancer.
  • The Triple Negative Breast Cancer Foundation was founded in 2006, with their friend named as the honorary founder. They provide funds and services for researchers and patients, including symposia,CME courses, research grants, webinars, and teleconferences on the latest treatments, and an online discussion forum for patients.
  • Hayley works to educate patients, HCPs, nurses and the community about TNBC via online discussion forums, and patient conferences. She works to meet the patients financial and social needs via a helpline with specially trained oncology social workers.
moniquegary2x
Monique Gary

MD/ Grandview Health system

  • Dr. Gary is a board-certified, fellowship-trained breast surgical oncologist and Medical Director of the Grandview Health/Penn Cancer Network Cancer Program. She is an advocate and expert on health and healthcare disparities, she's passionate about developing integrative, holistic and innovate approaches to cancer treatment, prevention and general wellness.
  • Dr. Gary is the only African American female breast surgical oncologist in the state of Pennsylvania.
  • Nationally, she serves on the board of directors for the American Society of Breast Surgeons. Dr. Gary was recognized as a Leading Physicians of the World and Top Breast Surgeon in Pennsylvania for 2017, 2018 and 2019, and is a Fellow of the American College of Surgeons, the highest distinction awarded to surgeons in the nation.
valerieb
Valerie B.

Patient Advocate TOUCH and TNBC Foundation

  • Valerie was diagnosed with Stage 2, triple-negative breast cancer in early 2018. After finishing treatment, Valerie's sister urged her to attend an event she found online, the 2018 Living Beyond Breast Cancer Conference: Sharing Wisdom, Sharing Strength, which was supported by the Triple Negative Breast Cancer Foundation.
  • Valerie was so inspired by the connections she made with other women at the conference and the stories they shared, Valerie got involved as a patient advocate and in 2019 received the Courage Award from the Triple Negative Breast Cancer Foundation.
  • Valerie is a TNBC survivor and patient advocate that supports TOUCH and TNBC Foundation in their efforts to raise awareness around TNBC research efforts and resources for patients and their families.
ogorii2x
Ogori Kalu

MD / St. Michael's Medical Centre

  • Dr. Kalu is a fellowship-trained Breast Surgical Oncologist and breast health specialist. She is dedicated to breast health education and breast cancer treatment in minority communities. Her interests are centered around breast cancer and health care disparities.
  • Her practice offers comprehensive breast care, including cancer and non-cancerous breast concerns,breast biopsies, consultations on abnormal mammograms, and all other breast health issues. She also specializes in gynecomastia (male breast tissue). Genetic testing and high-risk breast cancer screening are also offered.
melissadavis2x
Melissa Davis

PhD / Weill Conell Medicine

  • Dr. Davis is an Assistant Professor of Cell and Developmental Biology, Department of Surgery, Scientific Director of the International Center for the Study of Breast Cancer Subtypes, Weill Cornell Medical College and co-author of more than 20 peer-reviewed scientific journal articles.
  • She is a classically trained molecular geneticist with expertise in genomics and systems biology. She uses this skillset to unravel the multifocal contributions to cancer risk, disparities in clinical oncology outcomes and link this information back to genetic ancestry, particularly Sub-Saharan West African Ancestry.
  • Her research interests are to identify biological mechanisms of racial disparities in cancer risk and clinical outcomes of cancer diagnoses.

* Council members listed here, including Health Care Providers, are expressing support for clinical trials in general and are not endorsing any Gilead specific clinical trials or any listed here.

Council members listed here are compensated by Gilead and may or may not have received Gilead medications.

All patients have different experiences fighting cancer and in their treatment journey. Your experience is unique to you and may differ from the experiences shared here. This Gilead website does not, and is not intended to, provide medical advice.

YOUR QUESTIONS ANSWERED

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

YOUR QUESTIONS ANSWERED

FAQ Topic:
ALL Clinical Trial Basics Safety and Security Trial Terms Defined The Clinical Trial

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

All trials have different timelines due to various factors, such as the trial phase, study design, treatment duration or health condition being studied. During the consent process before enrolling, the research team will explain the specifics about the trial.
Due to the many differences in insurance plans across the country, coverage in clinical trials can vary. You will learn more about your options during pre-screening.
If you are living with a medical condition, joining a clinical trial may give you access to a new potential treatment before it is publicly available. Just as importantly, it can help researchers understand how this potential treatment affects the body and increase their knowledge about the disease and how to treat it. Participation can also play a vital role in helping others who have a similar condition, both now and in the future. Healthy volunteers in trials contribute to this medical progress as well by helping understand the effect of the potential treatment and any safety concerns.
As with all medical records, participant privacy and confidentiality in trials are protected by law. Once consent is signed, you will be given a trial code. Your trial records will not include your name or personal identity but will identify you with a trial code. This code can only be tracked back to you via a code key which is held by the responsible physician. Your name or personal identity will never be disclosed.
Yes, participants are volunteers and may withdraw from a clinical trial at any time.
A placebo is an inactive version of an intervention that is not intended to provide any medical benefit. It is designed to look the same as the active intervention, so the participant and research team do not know it is a placebo. The placebo is used by comparison to confirm any effects of the intervention being studied, if no approved intervention is available.
"Standard of care" is an intervention already approved for a specific health condition that is available publicly. Interventions in a clinical trial are still being tested to ensure safety and effectiveness.
Some clinical trials are designed to be "double blind" so both participants and researchers are unaware of which treatment group participants are assigned to. This prevents bias from affecting clinical trial data.
Your informed consent is required before being enrolled in a trial. This means you have been provided all relevant information about the study design, how you will participate, your right to withdraw at any time, study alternatives, your personal data protection and the associated risks and benefits. Informed consent is designed to protect patient safety and privacy.
Under FDA regulations, an Institutional Review Board (IRB) is a group that has been formally designated to review and monitor research at a hospital or institution involving human participants. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in, or disapprove research.
Participants are always welcome to visit their usual healthcare providers during a trial. Sometimes, it is important for healthcare providers to collaborate with the research team to ensure success.
After your participation ends, the study may continue for months or years. Once final results from all participants are compiled and analyzed, they are often published publicly. Clinical study report (CSR) synopses and plain language summaries (PLSs) may be made available for certain studies. Check with your clinical trial site or send an email to [email protected] to learn more.
There are a wide variety of professionals involved with any clinical trial, all of whom are vital to ensuring safety and success. The principal investigator, or PI, leads the trial and directs the team of doctors, nurses and other healthcare workers. The clinical trial coordinator manages day-to-day activities and is the main contact for participants. Many clinical trials also have an independent Data and Safety Monitoring Board (DSMB) who periodically reviews data to ensure participant safety, and sometimes effectiveness.
If you don’t qualify because you don’t meet the trial criteria, consider discussing other options with your healthcare provider or the patient’s physician would need to submit a managed access request based on the eligibility. Click here to learn more.